KPV (Alpha-MSH Fragment) dosing & administration
Anti-inflammatory tripeptide from alpha-melanocyte-stimulating hormone targeting NF-κB and gut inflammation
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Dosing
How much do I take?
Subcutaneous: A small injection into the fatty layer just under the skin — the same way insulin is given.
Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.
2 documented dose levels — separate regimens, not a titration schedule
200 mcg
Frequency
Once daily
Duration
4-6 weeks
300-500 mcg
Frequency
Once daily
Duration
4-6 weeks
Most commonly used subcutaneous practice dose for systemic/extra-intestinal inflammation; some practitioners escalate toward 500 mcg during acute flares [6].
Timing
Best time to take
Take KPV (Alpha-MSH Fragment) at the same time each day for consistent blood levels. Morning dosing with breakfast is often preferred, but follow your healthcare provider's specific instructions.
With food?
KPV (Alpha-MSH Fragment) can typically be taken with or without food. Taking it with a light meal may help reduce any GI discomfort. Avoid taking with grapefruit juice or high-fat meals unless specifically directed.
If stacking
KPV (Alpha-MSH Fragment) should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Adjusting your dose
Increase if
- You've tolerated the current dose for the recommended period without significant side effects
- Therapeutic goals haven't been met at the current dose level
- Your healthcare provider recommends dose escalation based on your response
- Lab work or clinical assessments support a higher dose
Decrease if
- Side effects are bothersome or impacting daily life despite management strategies
- You experience any signs of an adverse reaction
- Lab results indicate the need for dose reduction
- Your healthcare provider recommends a lower dose based on your response
Signs of right dose
- Therapeutic goals being met with minimal side effects
- Stable and consistent response to treatment
- Lab values or clinical markers trending in the right direction
- Good tolerance with manageable or absent side effects
Administration
How do I use it?
Reconstitution
What you need
Injection
Route
KPV (Alpha-MSH Fragment) is administered Oral—no injection required
Best sites
Storage
Before reconstitution
Store KPV (Alpha-MSH Fragment) in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
After reconstitution
Once reconstituted, KPV (Alpha-MSH Fragment) should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Signs of degradation — discard the vial
Sample daily schedule
As prescribed (once daily)
As prescribed by your healthcare provider injection
Site: Oral—rotate sites if applicable
Maintain a consistent schedule for optimal results with KPV (Alpha-MSH Fragment). Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.
Safety
Is it safe?
Side effects
Commonly reported: Injection Site Reaction, Mild GI Effects, Transient Skin Effects, Mild Immune Modulation, Peptide Stability Concerns
Less common: Theoretical Immunosuppression
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with KPV (Alpha-MSH Fragment)
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
KPV (Alpha-MSH Fragment) should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Flagged pairings
- High-Dose Immunosuppressants — Additive immune suppression may increase infection risk through overlapping anti-inflammatory mechanisms
- Melanotan Peptides — Potential overlapping melanocortin receptor activation could produce unpredictable combined effects
- Systemic Corticosteroids — Redundant anti-inflammatory pathways may confound therapeutic outcomes or cause excessive immune suppression
Published research
What the studies show
Sun J, et al. · 2021
A novel hydrogel delivery system stabilized KPV for ulcerative colitis treatment, showing 50% reduction in colonic myeloperoxidase activity in rat models. Intestinal epithelial barrier function was preserved, preventing disease progression.
Xiao B, et al. · 2017
Hyaluronic acid-nanoparticles delivered KPV directly to inflamed intestinal epithelium, achieving stronger anti-inflammatory effects than standard delivery. TNF-α was significantly downregulated, demonstrating targeted efficacy.
Brzoska T, et al. · 2008
This comprehensive review established KPV as a potent anti-inflammatory tripeptide derived from alpha-MSH that lacks the pigmentary effects of the parent hormone. KPV shows promise for treating inflammatory bowel disease, fibrosis, and arthritis.
Kannengiesser K, et al. · 2008
Original preclinical research demonstrated KPV efficacy in multiple murine inflammatory bowel disease models with approximately 50% reduction in colonic myeloperoxidase activity. The mechanism involved NF-κB pathway inhibition.
Brzoska T, et al. · 2010
Analysis revealed KPV's anti-inflammatory effects work through NF-κB and MAP kinase pathway inhibition—the same mechanism as full-length alpha-MSH but without unwanted side effects. KPV represents a minimal anti-inflammatory fragment.
PeptidesExplorer (practitioner protocol compilation) · 2026
Documents commonly used research/practice KPV doses: 200-500 mcg subcutaneous daily, 1000-1500 mcg oral daily for gut inflammation, and 0.01-0.1% topical formulations twice daily; notes no completed human trial has established an official dose.
Head to head
KPV (Alpha-MSH Fragment) compared
Want the full picture?
The complete KPV (Alpha-MSH Fragment) research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.